Pfizer settlement in EpiPen US antitrust case gets preliminary approval
MLex Summary: Pfizer’s $345 million settlement to resolve consumer plaintiffs’ claims that it conspired to delay generic EpiPen competition has been granted preliminary approval by a US judge.See document below. ...To view the full article, register now.
Already a subscriber? Click here to view full article